Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 206

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 206
---
 in light of the circumstances in which it was made. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus. You may request, and we will provide you with, a copy of these filings, at no cost, by calling us at (202) 327-5422 or by writing to us at the following address: 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW Suite 1000
Washington, D.C. 20036 Attn: Geoffrey Dow, Chief Executive Officer and President 127 60 DEGREES PHARMACEUTICALS, INC INDEX TO FINANCIAL STATEMENTS

| Report                                                                                                      
 of Independent Registered Public Accounting Firm                                                            
 Audited                                                                                                     
 Consolidated Balance Sheets at December 31, 2024 and 2023                                                   
 Audited                                                                                                     
 Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023 |     | F-2 
 F-3 
 F-4 |
|:------------------------------------------------------------------------------------------------------------|:----|:----|
| Audited                                                                                                     
 Consolidated Statements of Shareholders’ Equity for the years ended December 31, 2024 and 2023              |     | F-6 |
| Audited                                                                                                     
 Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023                        |     | F-7 |
| Notes                                                                                                       
 to Audited Consolidated Financial Statements                                                                |     | F-8 |

F-1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of 60 Degrees Pharmaceuticals, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of 60 Degrees Pharmaceuticals, Inc. and subsidiary (“the Company”) as of December 31, 2024 and 2023, and the related statements of operations and comprehensive loss, shareholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2024, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2024